The Fasting Study - Unraveling the mechanistic effects of prolonged fasting in humans.

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 24

Inclusion Criteria

- Apparently healthy man or woman
- Age 40-70y at the time of recruitment
- BMI of 22-30 kg/m2
- Willing to fast for 26 hours
- Willing to give blood samples
- Willing to give adipose tissue biopsies
- Willing to consume the standardized meal on test day 1
- Signed informed consent
- Having a general practitioner

Exclusion Criteria

- Alcohol on average: more than 2 consumptions/day or more than 14 consumptions/week
- Tobacco smoker
- Usage of drugs
- Following a diet within one month of the start of the study (for example a ketogenic diet)
- Allergic to one or more components of the standardized meal
- Donated or intend to donate blood from 2 months before the study until the end of the study
- Unstable body weight (weight gain or loss >5 kg in the past three months)
- Diagnosed with any long-term medical condition that can interfere with the study outcome (i.e. cardiovascular disease, diabetes mellitus type 1 or 2, liver, pulmonary, or renal disease)
- Use of prescribed medication
- Use of supplements or over the counter medication (OTC) known to interfere with glucose or lipid homeostasis in the week before the start of the study, and during the study
- Being pregnant or lactating
- Participation in another biomedical study within 1 month before the first screening visit (other than the EetMeetWeet study)
- Members of the research team, or first degree family members of the research team
- Working, or doing an internship at the division *Human Nutrition and Health* - Wageningen University

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- ANGPTL4 protein expression (plasma, adipose tissue)<br /><br>- ANGPTL4 gene expression (circulating immune cells, adipose tissue)<br /><br>- LPL protein expression (adipose tissue)<br /><br>- LPL gene expression (circulating immune cells, adipose tissue)<br /><br>- LPL activity (adipose tissue) </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- gene expression patterns (circulating immune cells, adipose tissue)<br /><br>- post-transcriptional changes (circulating immune cells, adipose tissue)<br /><br>- Markers of metabolic status, such as adipose tissue health and<br /><br>cardio-metabolic risk factors (plasma/serum, adipose tissue) </p><br>